CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic
May 15th 2018 CellCentric has raised $26 million in private financing to fund clinical testing…
read more
CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer. CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
